GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

ToolGen 199800.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

30,150

+6.91%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About ToolGen

Its shares trade on KOSDAQ under the ticker 199800.KQ. It has been listed since 25 June 2014. In the fiscal year to 31 December 2025, it reported revenue of ₩1.31bn and a net loss of ₩36.76bn. At that date it held total assets of ₩61.65bn and shareholders' equity of ₩55.85bn.

ToolGen, Inc. engages in the development of biotechnological products. The company is headquartered in Seoul, Seoul. The company went IPO on 2014-06-25. The Company’s main products portfolio consists of ribose nucleic acid (RNA)-guided endonucleases (RGEN) as well as deoxyribonucleic acid (DNA)-directed RGEN (dRGEN), which are applied as tools for editing genetic information in microbial, plant, animal and human cells. In addition, it is involved in the provision of genome engineering services.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Jun 2014
Employees
85
Website
toolgen.com ↗

Leadership

Pay as last reported

  • Mr. Byeong Hwa LeeChief Executive Officer, Director, since 2018
  • Ms. Yu Ri KimVice President, Chief Legal Officer, Director, since 2021
  • Mr. Ji Hak HanManaging Director
  • Mr. Gyeong Seong MinInternal Auditor, Director, since 2019
  • Mr. Seok Jung KimAssistant Managing Director₩5.35bn
  • Mr. Yil Ho HaOther Non-Executive Director
  • Mr. Seong Jun HongOther Non-Executive Director
  • Mr. Chang Gyu KimOther Non-Executive Director
  • Jin Su KimOther Non-Executive Director
  • Mr. Jun Seong ChoIR Contact Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • ToolGen develops ribose nucleic acid guided endonucleases for genetic editing.
  • The company provides deoxyribonucleic acid directed RGEN tools for cells.
  • ToolGen offers genome engineering services to various scientific sectors.

Weaknesses

  • The firm has only eighty-five employees in its workforce.
  • ToolGen is headquartered in Seoul, which may limit reach.
  • The company went public on twenty-fifth June twenty-fourteen.

Opportunities

  • Genetic editing tools can be applied to microbial cells.
  • Plant cells represent a significant segment for RGEN application.
  • Animal cells offer another market for genome engineering services.

Threats

  • Human cells require strict regulatory compliance for editing tools.
  • Seoul location might face competition from global biotech firms.
  • Only eighty-five employees may limit rapid product development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.